AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 1 - (NewsRx.com) -- Tumor cells genetically altered to express CD80 and certain interleukins (IL) can be used to enhance the efficacy of tumor vaccines against cervical cancer, according to a recent study.
"Tumor cells fail to activate specific cytotoxic T lymphocytes due to lack of co-stimulatory molecules, e.g., CD80 (B7.1)," stated A.M. Kaufmann and colleagues, Loyola University, Illinois. "We were able to render cervical carcinoma cells immunogenic by introduction of the CD80 gene into the tumor cells. In order to enhance the efficiency of T-cell activation we investigated whether addition of interleukins would augment immunostimulation by CD80."
Kaufmann et al. published the results of their study in the journal Immunobiology ("Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells," Immunobiol, 2000;202(4):339-352).
The researchers stimulated allogeneic T cells with CD80-expressing HeLa cells or CaSki cells. This was done in the absence or presence of IL-2, IL-7, IL-12, or the interleukins in several different combinations.
Next, they evaluated the proliferative response of the T cells. They observed that CD80-transduced HeLa or CaSki cells were capable of inducing a stronger proliferative response in allogeneic T cells than parental or mock transfected control cells.
Any of the three tested interleukins enhanced the proliferative response of allogeneic T cells to CD80-expressing tumor cells. They reported that IL-2 or ...
Source: HighBeam Research, Cytokines and CD80 Enhance Immunogenicity of Cell Vaccine.